The Merck Group Website
The Merck Group Website

Immuno-Oncology: Investigating Cancer Therapies Powered by the Immune System

Immuno-Oncology: Investigating Cancer Therapies Powered by the Immune System

Immuno-oncology focuses on harnessing the body’s immune system to mount an immune response against cancer.

At EMD Serono, we are deeply committed to changing the cancer landscape. Our immuno-oncology (iONC™) research and early development platform, integrating research, early development and biomarker strategies, focuses on discovering and developing potential new therapies that are intended to harness the immune system and activate or augment the body’s natural anti-tumor response.
Our comprehensive, science-driven strategy has been embodied within three focused areas of research:
  • therapeutic cancer vaccines (also called antigen-specific cancer immunotherapy)
  • cancer stem cells
  • tumor immunotolerance
At EMD Serono, we believe that the combination of therapies targeting different tumor escape mechanisms can change the way we treat a complex disease such as cancer in the future.
We are committed to delivering on the promise of immuno-oncology by combining creative thinking with strong research and clinical excellence, and, most importantly, by keeping patient needs at the heart of our efforts
top

Innovation Clusters

The comprehensive, science-driven strategy of the immuno-oncology platform has been embodied within three focused areas of research, each called an innovation cluster:
Innovation Cluster: Therapeutic Cancer Vaccines (also called antigen-specific cancer immunotherapy)
Therapeutic cancer vaccines seek to stimulate a specific immune response against a tumor and generate immunological memory to keep the tumor in check.
The development of cancer vaccines involves first identifying tumor-associated antigens that are capable of generating anti-tumor immune responses and then formulating these antigens into investigational agents for clinical testing against the tumors.
Innovation Cluster: Tumor Immunotolerance
Tumors develop diverse mechanisms that allow them to stay unrecognized by natural immune surveillance and escape elimination by the immune system. As a consequence, tumors grow and metastasize unconstrained.
By modulating these immunosuppressive mechanisms, the tumor immune environment can be shifted from an “immune tolerant” state toward an “immune activated” state and the immune system may be redirected to eliminate the cancer cells.
EMD Serono is targeting specific mechanisms of tumor immune suppression for therapeutic intervention. These therapies are designed to attempt to eliminate or circumvent inhibitory mechanisms in the immune system.
Exploring mechanisms of tumor inflammation is another core component of this innovation cluster. The inflammatory signals present in a tumor directly influence the composition of the immune cell infiltrate, the way the immune cells interact with each other and with tumor cells, and the milieu of soluble factors that influence tumor growth, invasion and immunosuppression.
Innovation Cluster: Cancer Stem Cells  
Cancer stem cells represent a rare population of tumor cells required for perpetuating tumor growth.
Cancer stem cells can migrate from a primary tumor into the blood stream and travel throughout the body, resulting in the formation of tumor metastases at distant sites. Cancer stem cells are thought to be a cause of disease recurrence due to their inherent drug-resistance and ability to lie dormant for long periods of time.
Therapies that eliminate cancer stem cells are an area of research and investigation.
top

Pipeline

The current immuno-oncology portfolio comprises therapeutic candidates in early clinical development and a pipeline of preclinical molecules. Leading therapeutic concepts in the clinic are*:  
Substance Status: June 2013 Target Related clinical trials
A monoclonal antibody targeting PD-L1 (programmed cell death ligand) expressed by various tumors Phase I Solid tumors ClinicalTrials.gov
NHS-IL12**, a cancer immunotherapy targeting IL-12 to necrotic regions of tumors Phase I complete Solid tumors ClinicalTrials.gov
NHS-IL2, a cancer immunotherapy targeting IL-2 to necrotic regions of tumors In preparation for Phase II Solid tumors
* Pipeline products are under clinical investigation and have not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indication.
** Sponsored by the United States National Cancer Institute (NCI).
top

Immuno-Oncology Leadership

EMD Serono has brought together a dedicated group of preeminent scientists and clinicians to lead the immuno-oncology innovation platform.

Helen Sabzervari, Ph.D.
Senior Vice President, Immuno-Oncology, Global Research and Early Development


Jean-Marie Cuillerot, M.D.
Head of Early Clinical Development


Robert Hofmeister, Ph.D.
Head of Translational Immmunotherapy


Kin-Ming Lo, Ph.D.
Head of ImmunoTechnology


Michael Wolf, Ph.D.
Head of Emerging Immunotherapy

EMD SERONO-SITC CANCER IMMUNOTHERAPY CLINICAL FELLOWSHIP AWARD

We’re pleased to offer a new opportunity with the Society for Immunotherapy of Cancer (SITC), The EMD Serono-SITC Cancer Immunotherapy Clinical Fellowship Award, available to individuals holding an MD or combined MD/PhD degree. For more information, including eligibility requirements and the application form, please visit the SITC website

COMMITTED TO PATIENTS

The hallmark of our immuno-oncology program is our commitment to patients. From research through clinical development, patient needs are at the heart of our research efforts.

JOIN OUR LEADING POSTDOCTORAL PROGRAM

Postdoc Program
Seize an unrivaled opportunity to be at the forefront of the field of immuno-oncology, working with some of the world's most well-known scientists.

SERVICES